Platelet activation and responsiveness in patients with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD)

Platelet activation and responsiveness in patients with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) - AE-COPD reactivity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45449

Enrollment

Registered

2017-03-01

Start date

2017-01-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD - obstructive lung disease

Interventions

cardiovascular risk

COPD

platelet activation

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study the COPD subjects must meet all of the following criteria: * >40 years * Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC

Exclusion criteria

Exclusion criteria: * Use of anti-coagulation, aspirin or platelet function inhibitors, with the exception of cyclooxygenase inhibitors (e.g, carbasalate calcium, acetylsalicylic acid) * Asthma * Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE) * Malignancies

Design outcomes

Primary

Measure	Time frame
1/2) Platelet activation: platelet expression of the platelet activation marker CD62P (P-selectin) and binding of fibrinogen to the activated fibrinogen receptor (IIb3) at baseline and upon stimulation with different platelet agonists. 3) Platelet-monocyte complexes. 4) Tissue factor (TF) triggered thrombin generation. 5) Soluble (plasma) markers of platelet activation and inflammatory cytokines.	—

Measure

Time frame

1/2) Platelet activation: platelet expression of the platelet activation marker CD62P (P-selectin) and binding of fibrinogen to the activated fibrinogen receptor (*IIb*3) at baseline and upon stimulation with different platelet agonists. 3) Platelet-monocyte complexes. 4) Tissue factor (TF) triggered thrombin generation. 5) Soluble (plasma) markers of platelet activation and inflammatory cytokines.

—

Secondary

Measure	Time frame
Please see the section primary study parameters	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)